BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease
Retrieved on:
Wednesday, September 2, 2020
Research, Medical devices, Infectious diseases, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, Science, Branches of biology, Biology, Bacteriology, Microbiomes, Environmental microbiology, Microbiology, Biomarker, Cell biology, Microbiota, Human gastrointestinal microbiota, Human Microbiome Project, Metatranscriptomics, the XMarker Discovery Platform, BiomX
As part of the collaboration, BiomX will generate metagenomic data of gut microbiome samples obtained from IBD patients with the aim of identifying biomarkers using the XMarker platform.
Key Points:
- As part of the collaboration, BiomX will generate metagenomic data of gut microbiome samples obtained from IBD patients with the aim of identifying biomarkers using the XMarker platform.
- Recent successes in the field of microbiome-targeted clinical development have further demonstrated the importance of the microbiome for human health.
- Beyond IBD, the XMarker platform has applications in major disease areas such as liver disease and cancer where microbiome composition is increasingly recognized as a potential contributing factor.
- The terms of the collaboration also include an option for Boehringer Ingelheim to negotiate an exclusive right to biomarkers discovered utilizing the XMarker platform.